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Objective. Examine the effectiveness of the 128Hz tuning fork, twomonofilaments, andNorfolk Quality of Life Diabetic Neuropathy
(QOL-DN) questionnaire as tools for the early detection of diabetic peripheral neuropathy (DPN) in overweight, obese, and inactive
(OOI) adults or those who have prediabetes (PD) or type 2 diabetes (T2D). Research Design andMethods. Thirty-four adults (mean
age 58.4 years± 12.1) were divided by glycemia (10 OOI normoglycemic, 13 PD, and 11 T2D). Sural nerves were tested bilaterally
with the NC-stat DPNCheck to determine sural nerve amplitude potential (SNAP) and sural nerve conduction velocity (SNCV).
All other testing results were compared to SNAP and SNCV. Results. Total 1 g monofilament scores significantly correlated with
SNAP values and yielded the highest sensitivity and specificity combinations of tested measures. Total QOL-DN scores
negatively correlated with SNAP values, as did QOL-DN symptoms. QOL-DN activities of daily living correlated with the right
SNAP, and the QOL-DN small fiber subscore correlated with SNCV. Conclusions. The 1 g monofilament and total QOL-DN are
effective, low-cost tools for the early detection of DPN in OOI, PD, and T2D adults. The 128Hz tuning fork and 10 g
monofilament may assist DPN screening as a tandem, but not primary, early DPN detection screening tools.
1. Introduction
Diabetes can result in long-term health complications,
with one of the most common being microvascular dam-
age that leads to diabetic neuropathy (DN), which is an
insidious, variated pathology that affects multiple body
systems and increases amputation risk [1, 2]. A typical
form of DN is diabetic peripheral neuropathy (DPN),
which is known to be a primary cause of balance issues
[2–4], sensation loss in the feet [5], and a major contribu-
tor to nontraumatic lower limb amputations [2]. This
pathology is a particularly significant concern for individ-
uals with diabetes, as it is common and often leads to
disability, yet it is difficult to diagnose due to frequent
asymptomatic onset or unusual presentation [1, 2, 6–8].
DPN affects the nerve endings in the feet, hands,
and other regions of the body after an individual
has experienced frequent or extended hyperglycemia or
other pathologies that lead to the loss of various forms
of sensation [9–11].
Earlier detection of DPN in at-risk individuals and in
those with prediabetes (PD) or type 2 diabetes (T2D) allows
for potential better management through optimal interven-
tion and lifestyle changes [12–14]. Limited research has
sought to detect subclinical changes utilizing expensive and
nonportable nerve conduction units, but the discovery of early
changes in sensation using readily accessible, portable tools
has not been a primary focus [12, 15, 16]. DPN often develops
silently over time, making early detection and intervention
difficult [14, 17–19]. Earlier intervention would likely allow
for more positive outcomes, and low-cost tools to detect
symptomology before the diagnosis of PD or T2D may be
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useful. Several tools, such as the 128Hz tuning fork and the
1 g and 10 g monofilaments, have been successfully used for
screening and disease assessment in adults with PD and
T2D [20–26]. The Norfolk Quality of Life Diabetic Neuropa-
thy (QOL-DN) questionnaire, NC-stat DPNCheck, and
hemoglobin A1C testing (HbA1C) have been validated in
T2D and limited PD populations, making them likely
candidates for successful early screening efforts [1, 27–31].
While each measure has been shown to be reliable
and valid in adults with PD and T2D, overweight, obese,
and inactive (OOI) populations are also at high risk for
the development of T2D and associated complications
[19, 32]. Therefore, the aim of this study was to evaluate
the effectiveness of identifying early signs of DPN using
the 128Hz tuning fork, 1 g and 10 g monofilaments, and
QOL-DN questionnaire in adults who were OOI or had
PD or T2D.
2. Materials and Methods
2.1. Study Participants. Volunteer subjects were recruited by
flyers, email, word of mouth, and university-wide announce-
ments. Subjects were screened by phone for exclusionary
factors prior to reporting for testing. Potential subjects
then reported to the Old Dominion University Wellness
Institute for additional screening, informed consent, and
testing measures. Assignment to groups was based on cur-
rent HbA1C testing values obtained onsite during study
procedures. Individuals with a history of type 1 diabetes,
tobacco use, hepatitis B, hepatitis C, HIV, pregnancy,
damage to the lower extremities, nerve disease (other than
neuropathy), peripheral arterial disease, lower limb ampu-
tations, foot ulcers, or a serious medical condition that
would compromise subject safety or the integrity of the
study were excluded. Study procedures were approved by
the Old Dominion University Institutional Review Board
prior to recruitment, and subjects gave their informed
consent before participating.
2.2. Main Objective. This study was designed to examine the
effectiveness of the 128Hz tuning fork, 1 g and 10 g monofil-
aments, and QOL-DN questionnaire for the identification of
early signs of DPN in OOI, PD, and T2D study populations.
All testing results were compared to the SNAP and SNCV of
the NC-stat DPNCheck, which served as the criterion mea-
sure for the study.
2.3. HbA1C Testing. Participants followed hydration instruc-
tions for 24 hours (8–10 cups of fluid) and 2-3 hours (2-3
cups of fluid) prior to appointment times to avoid point
of care device (POCD) high total hemoglobin errors.
Finger-stick testing was performed with a DCA Vantage
2000 Analyzer (Siemens, Tarrytown, NY) and DCA Vantage
HbA1C test kits utilizing sterile techniques [33]. HbA1C
values and prior diagnoses were utilized to screen and
categorize subjects as follows: OOI 4.0–5.6%; PD 5.7–6.4%;
and T2D 6.5% and above [15, 34, 35].
2.4. NC-stat DPNCheck. Nerve conduction study procedures
utilized the POCD NC-stat DPNCheck (DPNCheck,
NeuroMetrix Inc., Waltham, MA) and followed previously
outlined methods [30]. The POCD test method utilized a
validated, bilateral examination of the lower extremities
to obtain SNAPs and SNCVs on large myelinated nerve
fibers [30, 31, 36]. The device allows for evaluation by
non-technologist personnel, assisting in DPN detection at
significantly earlier stages when compared to bedside tests
[31, 37, 38]. The device itself consists of four basic compo-
nents: (1) biosensors, which are flexible, single-use units
that facilitate nerve conduction, integrating temperature
monitoring, nerve signal transmission, and the correct
placement of the device; (2) an easy view monitor, which
is lithium battery driven, displaying data collected from
the biosensors; (3) a docking station that transmits data;
and (4) an on-call information system that analyzes dock-
ing station data through proprietary algorithms, providing
individualized reports.
Unique biosensor technology paired with the NC-stat
DPNCheck unit’s two probes allowed for quick onsite evalu-
ation in a matter of minutes. After skin preparation, the
probes were coated in conductive gel and applied directly to
the skin, posterior to the lateral malleolus. With the single
press of a button, the unit distributed 100mA of current,
which was detected by the single patient use disposable
biosensor. A built-in thermometer accounted for variances
in temperature between 23°C and 30°C and notified the
operator of skin temperatures too cold for testing, preventing
further use until appropriate temperatures were present. Up
to five individual nerve conduction study attempts per leg
were utilized to collect three sets of SNCV and SNAP values,
each providing individualized feedback based on the patient’s
age, height, and weight data. Device errors were not recorded;
however, zero readings were recorded by hand and reat-
tempts were made up to the 5-trial limit, as individual toler-
ance permitted. When individuals could not tolerate the
acquisition of 3 data points per leg, last observation carried
forward (LOCF) methods were employed to complete the
trial set [39]. Individual reports were generated and reviewed
with each participant after the study, with referrals to appro-
priate professionals as needed. The provided interpretation
guide for each report sets “normal” limits for each participant
based on internal algorithms. Study participants were
assigned “abnormal” nerve conduction study results if their
personal results were lower than their personal calculated
“normal” limit across both legs for SNAP or SNCV, indicat-
ing consistent and equal reduction across both limbs, or if the
participant had bilateral, consistent reduction across both
SNAP and SNCV values. The validity and effectiveness of
the NC-stat DPNCheck system has been confirmed in
prior research [31, 38]. This test served as a criterion stan-
dard for the study, and all other testing was compared to
this measure.
2.5. QOL-DN Questionnaires. The QOL-DN, a validated
instrument and method for assessing neuropathy and differ-
entiating between autonomic, large, and small fiber impair-
ments [1, 27, 29] through multiple subscore components,
was utilized with each participant. Individuals were given
the questionnaire in a quiet area of the testing facility where
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they could work undisturbed, at their own pace, until
completion [1, 27–29].
2.6. Tuning Fork Testing. A 128Hz tuning fork was used to
assess vibration perception [40, 41]. Familiarization, site
and method of testing, and all procedures for the “on/off”
method followed standardized protocols as outlined by the
Rapid Screening for Diabetic Neuropathy using the 128Hz
tuning fork [40–45] (the appendix). The timed tuning fork
method was employed bilaterally, using the same methods
as Perkins et al. [43]. The procedural execution of both sets
of tuning fork tests for peripheral neuropathy was performed
with the subjects lying in the supine position, with eyes closed
during testing [43, 44].
2.7. Monofilament Testing. Commercially produced 1 g and
10 g monofilaments (North Coast Medical, San Jose, CA)
were used with a standard lab testing table to evaluate sen-
sation perception. Monofilament storage and testing took
place in a temperature-controlled environment, within
the parameters established by previous research [46, 47]
(the appendix). Scheduling was spaced out over a period
of six weeks, with fewer than 10 subjects per day, followed
by a 1-day rest period before subsequent use. Monofilaments
were utilized to assess sensation according to standardized
guidelines [20, 44, 48]. Familiarization and testing proce-
dures followed the Canadian Diabetes Association for the
Rapid Screening of Diabetic Neuropathy guidelines for
10 g monofilament testing at the dorsum of the great toe,
proximal to the nail bed. These procedures were applied
to testing for the 4.17/1 g and 5.07/10 g monofilaments
(North Coast Medical, San Jose, CA). Standardized proce-
dures were used for familiarization, subject response
patterns, sites tested, number of stimuli, and score assign-
ments, with all testing performed with the subject lying
supine, eyes closed, on a laboratory testing table, retaining
shoes and socks until testing to maintain body tempera-
ture [20, 41, 43, 44, 48].
2.8. Statistical Analyses. Data analyses were performed using
SPSS version 22.0 for Windows (SPSS, Chicago, IL). Partici-
pants, group characteristics, SNAP, and SNCV are presented
as raw data. Criterion and dependent variable data were
logarithmically transformed to best achieve normality for
statistical analysis. Partial correlations were analyzed using
Spearman’s coefficients for the tuning fork, 1 g and 10 g
monofilaments, QOL-DN and NC-stat DPNCheck results,
to determine the relationship between the variables. Interpre-
tation of nerve conduction studies and diabetic neuropathy
across the study for means was based on a cutoff definition
of <6μV for sural nerve amplitude potential, bilaterally
[31]. Interpretation of nerve conduction studies was evalu-
ated case by case through the NC-stat DPNCheck software
report package, which provided individualized cutoff data
for each participant to determine “normal” or “abnormal”
status for evaluation, allowing for the transforming of data
into dichotomous variables when appropriate. Age, HbA1C,
and waist measurement (in cm) were controlled for within
analyses by recoding nonparametric variables within SPSS
before running statistical tests. ROC curves were calculated
from dichotomous variables in SPSS that were developed
from the participant data based on “rule in,” “rule out,” and
total QOL-DN scoring. Kruskal-Wallis H tests were used to
determine if there were differences between the three groups
with pairwise comparisons using Dunn’s (1964) procedure.
Alpha was set at p < 0 05 for all analyses.
3. Results
In total, 34 adults (10 males, 24 females) of varying ethnicities
[Caucasian (64.7%); African-American (12%)] participated in
the study and were assigned to one of the three groups based
on theirHbA1C values: 10 (29.4%) normoglycemicOOI adults
(6 females, 4 males; 59.6 years, ±13.0 years), 13 (38.2%) with
PD (11 females, 2 males; 56.4 years, ±12.2 years), and 11
(32.4%)with T2D (7 females, 4males; 59.6 years,±12.1 years).
Group characteristics included mean weight (OOI: 87.93 kg,
SD± 10.94 kg; PD: 98.03 kg, SD± 23.26 kg; and T2D:
101.30 kg, SD± 17.68 kg), mean BMI (OOI: 30.90 kg/m2,
SD± 3.17 kg/m2; PD: 34.20 kg/m2, SD± 6.71 kg/m2; and
T2D: 35.10 kg/m2, SD± 5.03 kg/m2), and mean HbA1C
(OOI: 5.3%, SD± .36%; PD: 5.9%, SD± .22%; and T2D: 7.8%,
SD± 2.12%). The ten males (29.4%) in the study had a mean
age of 61 years (SD± 13.53 years), a mean height of 1.745m
(SD± .08m), a mean weight of 105.90 kg (SD± 20.62 kg), a
mean BMI of 34.85 kg/m2 (SD ± 4.97 kg/m2), and a mean
HbA1C of 6.0% (SD± .96%). Twenty-four females (70.6%)
who participated in the study had mean group characteristics
of the following: mean age of 57.2 years (SD ± 11.58 years),
mean height of 1.66m (SD± .06m), mean weight of 89.4 kg
(SD ± 15.10 kg), mean BMI of 32.99 kg/m2 (SD± 5.67 kg/m2),
and mean HbA1C of 6.5% (SD± 1.79%).
Fifteen participants reported no prior diagnosis or knowl-
edge of hyperglycemia. Five had PD (based onHbA1C).With-
out specific recruitment for OOI, 33 of the 34 subjects in all
groups were overweight (9) or obese (24). Six individuals
reported prior neuropathy diagnosis, while 28 individuals
reported having no prior neuropathy diagnosis or knowledge.
Ten reported T2D-specific medication usage as part of their
personal medical plan, and two T2D subjects reported taking
a combination of T2D and neuropathy medications.
Group means for SNAP and SNCV did not significantly
vary by HbA1C level (data not shown). No significant dif-
ferences were evident among OOI, PD, and T2D groups
on SNAP and SNCV values (SNAP: RH(2) = 1.460, p = 0 482
and L H(2) = 2.369, p = 0 306; SNCV: R H(2) = 1.874,
p = 0 392 and L H(2) = 1.880, p = 0 391). Data means and
standard deviations are presented (Table 1(a)). Twenty-
seven individuals obtained confirmed, individualized, abnor-
mal NCS results, of which 25 were bilateral and symmetrical
(Table 2). Twenty-four participants presented with a combi-
nation of abnormal distal signs bilaterally, of which 2 also
reported altered activities of daily living (ADLS) and 4
reported autonomic symptoms. Only 2 of the 24 reported
changes in both ADLS and autonomic subscore features.
One individual presented with no signs or symptoms. Seven
cases presentedwith normalNCS findings, but in the presence
of reported symptoms and reduced bilateral distal sensation.
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The tuning fork on/off test did not correlate with crite-
rion variables used in this study (see Table 1(b) and
Table 3); however, the tuning fork achieved a sensitivity
of 50.0%, specificity of 75.0%, and positive predictive
value (PPV) of 69.2%. Timed tuning fork testing yielded
no significant correlations or relationships within the study,
bilaterally. The total 1 g monofilament scores moderately
correlated with both SNAPs [R: rs(34) = 0.364, p = 0 024;
L: rs(34) = 0.312, p = 0 047], and left 1 g monofilament
scores demonstrated a moderate relationship to both SNAPs
[R: rs(34) = 0.393, p = 0 016; L: rs(34) = 0.301, p = 0 053] and
the left 1 g monofilament also correlated to the left SNCV
(L: rs(34) =−0.313, p = 0 046) of the NC-stat DPNCheck.
Sensitivity for the 1 g monofilament was 66.7% with a
specificity of 72.0% and a PPV of 46.2% (see Table 1(b),
Figure 1, Table 3).
The 10 g monofilament did not significantly correlate to
criterion variables. Sensitivity for the 10 g monofilament was
47.4%, with specificity at 73.3% and a PPV of 69.2%. Total
QOL-DN scores negatively correlated with both SNAPs
[R: rs(34) =−0.317, p = 0 044; L: rs(34) =−0.311, p = 0 047],
as did the QOL-DN symptom subscale (both SNAPs)
[R: rs(34) =−0.332, p = 0 036; L: rs(34) =−0.375, p = 0 021],
yielding a sensitivity of 60.0%, specificity of 70.8%, and PPV
of 46.2% (Table 1(b), Table 3). The small fiber subscale of
the QOL-DN correlated with the RSCV [R: rs(34) =−0.311,
p = 0 047] and the QOL-DN ADLS subscale correlated with
the RSNAP both SNAPs [R: rs(34) =−0.354, p = 0 028].
QOL-DN components spanned a wide range in sensitivity
(36.4–60.0%) and specificity (60.9–100.0%), with PPV
ranging from 30.8 to 100% (Table 1(b), Figure 1, Table 3).
4. Discussion
The integration of these testing methods provided founda-
tional work necessary to develop a better understanding of
Table 1: NCS results.
(a) Sural nerve amplitude potentials and conduction velocities
N Min Max Mean Std. error Std. dev.
SNAP-R (μV)
OOI 10 2 14.3 6.631 1.444 4.567
PD 13 2 24.7 7.691 1.674 6.037
T2D 11 2 25 9.875 2.133 7.076
SNAP-L (μV)
OOI 10 2.3 21.7 7.129 1.834 5.798
PD 13 3 21.7 7.277 1.186 4.277
T2D 11 3 21.7 10.572 2.064 6.847
SNCV-R (μV)
OOI 10 35.3 55.7 46.2 1.902 6.016
PD 13 30 57 48.2 1.871 6.747
T2D 11 35.3 57 45.5 1.816 6.022
SNCV-L (μV)
OOI 10 41.3 55 47.265 1.519 4.803
PD 13 43 55 49.637 1.072 3.865
T2D 11 37.3 57 46.876 1.946 6.455
(b) Sensitivity and specificity of screening tests and subcomponents
Prevalence Sensitivity Specificity PPV∗ NPV∗
128Hz tuning fork 52.90% 50.00% 75.00% 69.20% 57.10%
1 g monofilament 26.50% 66.70% 72.00% 46.20% 85.70%
10 g monofilament 55.90% 47.40% 73.30% 69.20% 52.40%
QOL-DN total 29.40% 60.00% 70.80% 46.20% 81.00%
QOL-DN symptoms 32.40% 36.40% 60.90% 30.80% 66.70%
QOL-DN large fiber 35.30% 58.30% 72.70% 53.80% 76.20%
QOL-DN small fiber 97.10% 39.40% 100.00% 100.00% 4.80%
QOL-DN ADLS 76.50% 42.30% 75.00% 84.60% 28.60%
QOL-DN autonomic 61.80% 42.90% 69.20% 69.20% 42.90%
∗Normoglycemic, PD, and T2D. PPV = positive predictive value; NPV = negative predictive value; based off R/L SNAP values. Prevalence indicates presence of
findings for indications of neuropathy.
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the onset of dysfunctional physiological processes within
OOI, PD, and T2D populations during the beginning of
disease onset, shedding light on associations between symp-
toms and diseases. Moderate positive correlations were
found between the 1 g monofilament and total and left leg
scores with the recorded SNAP values. Additionally, the
total QOL-DN, ADLS, and symptom scores negatively and
moderately correlated to SNAPs, while small fiber scores
negatively moderately correlated to SNCV. These correla-
tions suggest that these tools may be useful for incorporation
into low-cost screenings.
Detecting diabetes complications is an unfolding evolu-
tion that involves multiple dynamics to consider. DPN may
present in a completely silent manner, without pain, burning,
or symptoms of annoyance, and the utilization of the
QOL-DN provides a unique, previously validated means
of evaluating symptomology in at-risk populations [2].
Assessing DPN as early as possible is key, as individuals
with early DPN may experience the disease in a varied
manner with some individuals experiencing asymptomatic
disease patterns, ultimately requiring hands-on screening
to identify the silent progression of the disease. Pairing
Table 2






Normal 7 1 3 3




Normal 14 3 6 5
Abnormal∗ 20 7 7 6
Monofilaments
1 g
Normal 3 1 0 2
Abnormal∗ 31 9 13 9
10 g
Normal 3 1 0 2
Abnormal∗ 31 9 13 9
Symptoms
N = 34
None reported 11 6 1 4
Reported∗∗ 23 4 12 7
Autonomic
N = 34
None reported 21 7 8 6
Reported∗∗ 13 3 5 5
ADLS
N = 34
None reported 26 8 10 8
Reported∗∗ 8 2 3 3
NCS, sign & symptom combinations
AbNCS, signs & symptoms 17 3 9 5
AbNCS, signs, or symptoms 9 5 1 3
AbNCS, no signs, or symptoms 1 1 0 0
NNCS, signs & symptoms 7 1 3 3
(b) SNAP values
Min Max Mean (SD) Std. error
SNAP-R (μV)
NNCS N = 13 7.300 25.000 14.022 ± 5.64 1.564
AbNCS∗ N = 21 3.618 5.202 4.41 ± 1.740 0.379
SNAP-L (μV)
NNCS N = 13 11.050 17.138 14.096 ± 5.033 1.396
AbNCS∗ N = 21 3.898 5.524 4.712 ± 1.786 0.389
∗Bilateral testing; abnormal findings on at least one limb. ∗∗Self-reported on QOL-DN. AbNCS: abnormal nerve conduction study; NNCS: normal
nerve conduction study. Part (a): AbNCS defined by NC-stat DPNCheck report values for SNAPs and SNCVs. Part (b): AbNCS defined by 6.0 μV
or less SNAPs.
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the QOL-DN with the 1 g and 10 g monofilaments and
128Hz tuning fork provided us with an opportunity to
explore previously validated tools in overweight, obese
subjects who were inactive and at risk for the development
of DPN.
This study utilized SNAP and SNCV values to evaluate
nerve function in participants. Sural nerve conduction and
amplitude values are validated quantitative physiological
markers that assist in the assessment and confirmation of
DPN status with or without the presence of signs or symp-
toms [30, 31]. Over 76% of participants in this study demon-
strated abnormal NCS, 24 of whom reported symptoms and
bilateral symmetrical signs upon examination that met the
requirements for confirmed DSPN [49]; this is a significant
percentage of participants in comparison to other research
using the same measures [31]. Using low-cost screening
tools, early DPN signs and symptoms were detected with a
combination of methods that can be used on site, reliably,
in a climate-controlled location. This is effectively different
than other research attempts to identify early DPN, such as
Mustafa et al., which required both blood work for C-
reactive protein (CRP) and traditional NCS sural nerve eval-
uation [15]. Utilizing the NC-stat DPNCheck, the QOL-DN
questionnaire, and QST measures, our investigation indi-
cated subclinical neuropathy, a strong presence of early DPN
signs, and pathology symptoms in the populations studied.
Other research has reported alternate findings, which
may be at least partially explained by differences in the pop-
ulations studied. Perkins et al. [31] only evaluated individuals
with diagnosed diabetes (type 1 and type 2), whereas our
study examined a wide range of subjects, including appar-
ently healthy individuals recruited for our OOI population
that may be prone to DPN, as well as adults with PD and
T2D [31]. The bilateral, abnormal findings present in 71%
of the individuals in this study have not been reported by
others at a similarly high prevalence.
Assessment in this study differed from previous research
by evaluating each individual participant according to age,
height, and weight to determine appropriate cutoffs for nor-
mal and abnormal findings. This method individualized
results to each participant with the built-in NC-stat software
and included the potential impact of being overweight or
obese. Having noted discrepancies between values of tradi-
tional NCS and the NC-stat DPNCheck, Lee et al. [30]
performed a study that analyzed both measures, noting
that the SNCV values tend to be lower with a traditional
Table 3: NC-stat DPNCheck Spearman’s partial correlations
(log transformed).
SNAP-R SNAP-L SNCV-R SNCV-L
N = 34 N = 34 N = 34 N = 34
Tuning fork
On/off 0.221 0.137 0.235 −0.089
p value 0.121 0.235 0.106 0.319
Timed R −0.066 −0.019 −0.019 −0.099
p value 0.365 0.461 0.459 0.302
Timed L −0.063 −0.052 −0.018 −0.081
p value 0.371 0.392 0.463 0.355
Monofilaments
Total 1 g 0.364∗ 0.312∗ −0.06 −0.141
p value 0.024 0.047 0.377 0.229
1 g R 0.229 0.206 0.024 0.077
p value 0.112 0.138 0.451 0.342
1 g L 0.393∗ 0.301∗ −0.191 −0.313∗
p value 0.016 0.053 0.155 0.046
Total 10 g 0.098 0.088 0.032 0.03
p value 0.304 0.321 0.432 0.438
10 g R 0.096 0.16 0.005 −0.066
p value 0.306 0.2 0.489 0.364
10 g L 0.137 0.07 0.031 0.054
p value 0.235 0.356 0.436 0.388
QOL-DN
Total −0.317∗ −0.311∗ 0.162 −0.117
p value 0.044 0.047 0.197 0.269
Symptoms −0.332∗ −0.375∗ 0.213 −0.003
p value 0.036 0.021 0.129 0.493
Large fiber −0.297 −0.284 0.107 −0.163
p value 0.056 0.064 0.286 0.195
Small fiber −0.241 −0.187 −0.311∗ −0.366∗
p value 0.099 0.161 0.047 0.023
ADLS −0.354∗ −0.263 0.104 −0.065
p value 0.028 0.08 0.293 0.366
Autonomic −0.236 −0.245 0.149 −0.044
p value 0.105 0.096 0.216 0.408
Accounts for HbA1C, age, and waist (cm).
∗Significance at p < 0 05.
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Figure 1: Receiver operator characteristics (ROC) curve.
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NCS when compared to the NC-stat DPNCheck. Given
that traditional NCS is the ultimate “gold standard,” if the
same type of error occurred in this study, it would likely
boost the number of individuals who had abnormalities
even higher.
To detect early DPN in normoglycemic OOI individuals,
it had been hypothesized that the 128Hz tuning fork and
QOL-DN would provide the best mechanisms for detection;
however, current results indicated only partial support for
this. The tuning fork on/off test did not correlate well with
the NC-stat DPNCheck SNAP criterion variables, although
the QOL-DN did yield correlational results on several mea-
sures. This finding is different than some prior research, as
the QOL-DN has not always been found to correlate with
electrophysiological measures [50, 51].
The QOL-DN ranged in sensitivity (36.4–60.0%) and
specificity (60.9–100.0%), differing from previous research
that resulted in high specificity and sensitivity. The small
fiber component weighed in with high specificity, yet overall,
specificity averaged 60.9–75.0% with the other components.
These results may have been affected by this study’s popula-
tion and its small number of subjects across three groups in
attempting to uncover DPN at the earliest point possible.
Previous research expressed concern relating to the QOL-
DN: Hogg et al. [52] reported the QOL-DN as a means to
aid in diagnosis and monitoring all types of diabetes neurop-
athy, but expressed a lack of specificity for PN, stating that it
may be limited in its use to directly assess health impacts of a
diabetes foot disease-related nature. Conversely, in this
study, QOL-DN measures not only significantly correlated
with DPN, but also provided vital standardized data relating
to self-reported symptoms.
The 1 g monofilament proved to be a useful tool, with
31 individuals in this study experiencing abnormal find-
ings. This measure indicated relatively high sensitivity
(66.7%) and specificity (72.0%). However, validation of
1 g physical findings was achieved with moderate correla-
tions back to the criterion SNAP variables, corroborating
previous research that reported mixed sensitivity and
specificity, such as Feng et al. and Taksande et al. [22, 53].
The 10 g monofilament testing lacked significant correla-
tional relationships, yet the usefulness of this tool has
been well established in T2D research and in limited PD
populations by others. The findings in this study did not
add support for its use in normoglycemic obese popula-
tions, but insensate feet relate to neuropathy in later
stages and this research focused on early detection. Cur-
rent findings did, however, somewhat parallel to Perkins
et al. [43], who achieved lower sensitivity (53%) with the
10 g monofilament. In contrast, Ylitalo et al. [54] found
that the 10 g monofilament was a useful tool for uncover-
ing neuropathy in obese individuals, yet that study only
examined women and allowed smokers and T1D subjects
within their study cohort, possibly accounting for some
differences in results.
The QOL-DN (S: 60.0%; SP: 70.8%) was hypothesized
to be the most sensitive measure to detect undisclosed
DPN in the study population; instead, the 1 g monofilament
(S: 66.7%; SP: 72.0%) performed slightly better within this
limited cohort. The 128Hz tuning fork on/off test (S: 50.0%;
SP: 75.0%) fell not too far behind. The QOL-DN proved to
be lower in sensitivity in this study and ranged in specificity,
yet many components (total QOL, symptoms, ADLS, and
small fiber) correlated to the criterion measure used. Sample
size was quite small, and with the significant previous valida-
tion history of the QOL-DN, it is likely that this screening
instrument in its entirety may be useful in determining
both small and large fiber deficits in a larger study in
overweight, obese, and inactive individuals [1, 50, 51, 55].
The criterion measure, the NC-stat DPNCheck, targets
screening for large fiber deficits and may not correlate as
well with a well-rounded screening measure that targets
multiple areas of neuropathy like the QOL-DN. Future
research should likely continue to examine the QOL-DN
for early DPN detection, as several subscales indicate sig-
nificant correlations.
There is a strong indication of early-onset and subclin-
ical neuropathy in the populations in this study, suggest-
ing that careful screening of individuals at earlier stages
may be quite beneficial in the early detection of DPN, even
prior to hyperglycemia onset in OOI and PD. Smith and Sin-
gleton [56] found elevated HbA1C status in such populations
to be a concern for the development of large fiber-related
neuropathy complications, in accordance with this cohort.
Diabetes-related complications, such as decreased motor
and sensory nerve conduction velocities, may arise out of
acute bouts of hyperglycemia experienced though post-
prandial excursions, which may be best reflected by
HbA1C values [9].
This pilot study has some limitations. Besides being
small, the cohort was limited to one site of investigation
and only two ethnic groups; therefore, its findings must be
placed within the context of the larger body of literature
available. Lack of random assignment and use of volunteers
for subjects created potential selection bias, with the use of
clinical populations and low available funding heavily
influencing these methods. HbA1C testing was performed
with a validated machine, yet oral glucose tolerance testing
is preferred by some researchers, particularly for individuals
with cardiac autonomic neuropathy (CAN) [57]. This study
did not test for CAN and, therefore, cannot account for
unknown discrepancies that could affect results. Tempera-
ture, humidity, and high-volume testing in short periods of
time have been found to affect the validity of monofilament
testing [46, 58]. Temperature was accounted for by limiting
monofilament storage and use to normal climate-controlled
room temperatures and the monitoring of these values.
While humidity was monitored, it was not controlled
beyond what the laboratory air conditioning and heating
systems accounted for. Monofilament usage followed pre-
viously stated guidelines and recommendations, with com-
bined testing amounting to less than 100 compressions per
day per instrument [58]. The NC-stat DPNCheck device
was used solely to test the sural nerve, as in the case of
Perkins et al. [31]; therefore, deficits in nerve function relat-
ing to other nerves of the lower leg were not confirmed
through this device and two nerves were not evaluated, as
some literature advises. The QOL-DN has been previously
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validated for individuals with diabetes and neuropathy, yet
its specific validation to effectively target OOI individuals
has not been performed and, therefore, this should be taken
into account when interpreting the findings.
Although we applied rigorous testing preparation and
methods, it is possible that there was an error we remain
unaware of that affects the validity of these findings [59].
It is also possible that the NC-stat DPNCheck current
software components and algorithms are too sensitive for
the subject population. For clarification, we compared our
SNAPs to Perkins et al. and found that, overall, SNAP values
in this study contained values ranging from 2 to 25μV, with
means ranging from 6.6 to 10.5μV, compared to Perkins
et al., who contained means of 5.6μV. Many of their
participants (16) had undetectable levels, whereas this study
obtained three readings on all but 4 individuals to whom
LOCF was applied. Acquisition of three readings on each
leg across a diverse collection of individuals, all of whom
were likely to develop DPN, likely increases the validity of
these findings. In further support, the individuals with
abnormal findings self-reported symptoms via QOL-DN
symptoms subscale and had documented distal sensation loss
via 128Hz tuning fork and 1 g or 10 g monofilaments.
Unique features of testing done in this study include
accounting for age, height, and weight individually, securing
a minimum of 3 readings per leg, therefore allowing a more
individualized and accurate assessment of the large myelin-
ated nerve fibers. Small fiber-associated deficits were not
directly assessed in this study. The testing done does offer a
nonclinical analysis based on the criteria required by Tesfaye
et al. aiming to achieve minimal definition requirements for
confirmed and subclinical DSPN classification, with the
intent of developing early screening measures for DPN-
prone populations [49].
5. Conclusions
In summary, early DPN signs and symptomology can be
detected in OOI, PD, and T2D populations using low-cost,
established tools. The 1 g monofilament proved to be more
useful for the early detection of DPN than the 10 g monofila-
ment within this population by correlating to the study
standard and providing the highest sensitivity and specificity
combination. The total QOL measure also proved to be
useful, correlating to the standard, yielding the second
highest combination of sensitivity and specificity to SNAP
and SNCV values. Several QOL-DN subscales (ADLS,
Small Fiber, Symptoms) provided valuable, standardized
information that can be incorporated into low-cost com-
munity screening models for early DPN detection in
populations with or without PD and T2D, while providing
varied sensitivity and specificity across multiple categories.
The 128Hz tuning fork did not prove to be quite as
accurate in this population as the QOL-DN and should
be used as a tandem measure when screening. Future
research should consider a larger study with the same
populations, aiming to continue to refine and develop
screening methods targeted towards disclosing both symp-
tomatic and asymptomatic DPN.
Appendix
A. Procedures for Screening for
Diabetic Neuropathy
A.1. Monofilaments, 1g and 10g. The participant was first
shown the monofilament, by allowing them to see it and then
gently touching their foreheadwith the instrument. Theywere
instructed to close their eyes and say “yes” each time that the
stimulus was felt. The monofilament was applied to the dor-
sum of the great toe, just proximal to the nail bed for approx-
imately one second, 4 times per foot, in an irregular pattern in
such away that the stimulus could not be anticipated. Scoring:
0 was assigned for no perception, 0.5 substantially less percep-
tion and 1 for normal perception. Totals: 0–3, the presence of
neuropathy is likely; 3.5–5 indicates that the onset of neurop-
athy within four years is high; 5.5 and above indicates low risk.
A.2. Tuning Fork – 128 Hz. The tuning fork was struck
against the palm of the testers hand so that it would vibrate
for approximately 40 seconds and then applied to the base
of the forehead so that participants could understand the
concept of the vibration sensation. After asking the patient
to close their eyes, the tuning fork was placed on the bony
prominence at the dorsum of the first toe, which is just prox-
imal to the nail bed. The participant was asked to report
when the vibration stopped, and the tester dampened the
tuning fork with the other hand. Scoring: 1 point was
assigned for each correct perception of (vibration “on” or
“off”). The procedure was performed twice on each foot in
such a way that the participants could not anticipate the tes-
ters actions. This is a “rule out” test for the presence of neu-
ropathy and does not indicate risks related to future onset.
This is adapted from the Canadian Diabetes Association,
Rapid Screening for Diabetic Neuropathy [44].
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